Showing results (81-90 of 205) with videos related to

Sort By:
Pageof 21
Bulletin Du Cancer|November 1, 2006
[Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]Ludwig Grangeasse, Bruno Coudert, Xavier Pivot, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 11, 2011
Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapySebastien Pili-Floury, Bernard Royer, Frederique Bartholin, et al.
Expert Opinion on Drug Safety|March 8, 2008
Anticancer therapy in patients with porphyrias: evidence todayAntoine Thiery-Vuillemin, Loic Chaigneau, Nadine Meaux-Ruault, et al.
Breast (Edinburgh, Scotland)|May 27, 2017
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trialJoseph Gligorov, Giuseppe Curigliano, Volkmar Müller, et al.
Clinical Drug Investigation|September 26, 2016
Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal TumorsVirginie Nerich, Camille Fleck, Loïc Chaigneau, et al.
Bulletin Du Cancer|January 22, 2017
[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys]François Eisinger, Xavier Pivot, Laurent Greillier, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 28, 2012
Specific anticancer treatments in the last 3 months of life: a French experienceErika Viel, Loïc Chaigneau, Eleonor Fanton, et al.
Bulletin Du Cancer|April 21, 2012
[Immunotherapy: an emerging strategies against prostate castration resistant cancer]Laura Mansi, Antoine Thiery-Vuillemin, Elsa Kalbacher, et al.
Medical Oncology (Northwood, London, England)|July 13, 2016
Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trialFabien Calcagno, Guillaume Mouillet, Olivier Adotevi, et al.
Breast (Edinburgh, Scotland)|July 6, 2011
Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trialXavier Pivot, Alain Lortholary, Sophie Abadie-Lacourtoisie, et al.
Pageof 21